Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
RemeGen Co. Ltd. Class H ( (HK:9995) ) just unveiled an announcement.
RemeGen Co., Ltd. announced the resignation of Dr. He Ruyi from his roles as an executive director, member of the strategy committee, chief strategic officer, and core technical personnel. His resignation, effective February 6, 2025, is due to personal career development and will not impact the company’s operations or board activities. The company has expressed gratitude for Dr. He’s contributions and plans to conduct a by-election for his replacement.
More about RemeGen Co. Ltd. Class H
RemeGen Co., Ltd. is a biopharmaceutical company based in China, focusing on innovative drug discovery and development. The company is listed on the Stock Exchange of Hong Kong and engages in the development of therapeutics for various medical conditions.
YTD Price Performance: -9.17%
Average Trading Volume: 1,556,837
Technical Sentiment Consensus Rating: Buy
Current Market Cap: HK$13.01B
For an in-depth examination of 9995 stock, go to TipRanks’ Stock Analysis page.
